Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
Displaying: 92 trials in your specialties ()
View trials across your selected specialties

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metas...
View Full Trial
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non-Hodgkin's Lymphoma, Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States

Brief Summary

The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    T Cell Lymphoma
View Full Trial
INTERVENTION

Drug: Tenalisib, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Brief Summary

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Colorectal Cancer
View Full Trial
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, Relapsed/Refractory T-cell Lymphomas
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Bortezomib, Drug: duvelisib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Stanford University Medical Center, Stanford, California, United States

Brief Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    T Cell Non-Hodgkin Lymphoma
View Full Trial
INTERVENTION

Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moffitt Cancer Center, Tampa, Florida, United States

Brief Summary

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
View Full Trial
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Brief Summary

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hiv
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: 3BNC117, Drug: Antiretrovirals

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Infectious Diseases, Aalborg, Denmark

Brief Summary

To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lympho...
View Full Trial
INTERVENTION

Drug: Pralatrexate, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Brief Summary

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with peripheral T-Cell lymphoma (PTCL).

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Peripheral T-cell Lymphoma
View Full Trial
INTERVENTION

Drug: Romidepsin + CHOP, Drug: CHOP

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

ZNA Stuivenberg, Antwerpen, Belgium

Brief Summary

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).